来自宫颈癌相关的16型人乳头瘤病毒的转化蛋白E7的表达、纯化及免疫学特性分析
Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16.
作者信息
Fernando G J, Murray B, Zhou J, Frazer I H
机构信息
University of Queensland, Department of Medicine, Princess Alexandra Hospital, Brisbane, Australia.
出版信息
Clin Exp Immunol. 1999 Mar;115(3):397-403. doi: 10.1046/j.1365-2249.1999.00813.x.
Abstract
E7 is the major oncogenic protein produced in cervical cancer-associated human papillomavirus type 16 (HPV16). This protein was expressed in Escherichia coli as a glutathione-S-transferase (GST) fusion protein. E7-enriched inclusion bodies were collected from bacterial lysates, were solubilized in 10 M urea, and the protein was purified using anion exchange column chromatography. After removal of endotoxin with serial Triton X-114 extractions, material of high purity (about 90%) was obtained, which is suitable for use in a human clinical trial. This material was immunogenic, and when used as a vaccine, protected mice against challenge with an HPV16 E7 DNA transfected tumour cell line. Based on this observation, the E7GST fusion protein is currently being used in a human clinical trial of a vaccine against HPV16-induced cervical cancer. This fusion protein could be cleaved with thrombin to remove the GST fusion part and further purified by preparative SDS gel electrophoresis to obtain free E7 with > 98% purity.
摘要
E7是与宫颈癌相关的16型人乳头瘤病毒（HPV16）产生的主要致癌蛋白。该蛋白在大肠杆菌中作为谷胱甘肽-S-转移酶（GST）融合蛋白表达。从细菌裂解物中收集富含E7的包涵体，将其溶解在10 M尿素中，然后使用阴离子交换柱色谱法纯化该蛋白。通过连续的Triton X-114萃取去除内毒素后，获得了高纯度（约90%）的材料，适用于人体临床试验。该材料具有免疫原性，用作疫苗时可保护小鼠免受HPV16 E7 DNA转染的肿瘤细胞系的攻击。基于这一观察结果，E7GST融合蛋白目前正在用于一项针对HPV16诱导的宫颈癌疫苗的人体临床试验。该融合蛋白可用凝血酶切割以去除GST融合部分，并通过制备性SDS凝胶电泳进一步纯化，以获得纯度>98%的游离E7。
相似文献
1
Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16.来自宫颈癌相关的16型人乳头瘤病毒的转化蛋白E7的表达、纯化及免疫学特性分析
Clin Exp Immunol. 1999 Mar;115(3):397-403. doi: 10.1046/j.1365-2249.1999.00813.x.
2
[Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].[人乳头瘤病毒16L/E7融合蛋白在大肠杆菌中的表达及其在小鼠体内免疫原性的观察]
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006 Jun;20(2):33-7.
3
Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model.修饰的人乳头瘤病毒16 E6/E7融合蛋白的高效表达及其在小鼠模型中的抗肿瘤疗效
Biol Pharm Bull. 2004 Mar;27(3):303-7. doi: 10.1248/bpb.27.303.
4
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.通过给予包含牛分枝杆菌卡介苗（BCG）热休克蛋白65（hsp65）和人乳头瘤病毒16型（HPV16）E7的融合蛋白对表达HPV16 E7的肿瘤进行免疫治疗。
Clin Exp Immunol. 2000 Aug;121(2):216-25. doi: 10.1046/j.1365-2249.2000.01293.x.
5
Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.基于树突状细胞的宫颈癌疫苗I：用重组蛋白脉冲树突状细胞进行体外刺激可诱导针对HPV16 E7或HPV18 E7的特异性T细胞。
J Cancer Res Clin Oncol. 2003 Sep;129(9):511-20. doi: 10.1007/s00432-003-0462-6. Epub 2003 Aug 2.
6
Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.编码嵌合型乙型肝炎病毒表面抗原-16型人乳头瘤病毒E7蛋白的低剂量腺病毒疫苗可诱导增强的E7特异性抗体和细胞毒性T细胞反应。
J Virol. 2005 Oct;79(20):12807-17. doi: 10.1128/JVI.79.20.12807-12817.2005.
7
[Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].共表达人乳头瘤病毒16型L1/L2/E6/E7蛋白的非复制型重组痘苗病毒的构建与鉴定
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):240-3.
8
Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.通过密码子优化构建的编码16型人乳头瘤病毒（HPV16）DNA的质粒提高了针对HPV感染的免疫原性。
Vaccine. 2004 Dec 16;23(5):629-38. doi: 10.1016/j.vaccine.2004.07.010.
9
Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.人乳头瘤病毒 16 L1-E7 嵌合病毒样颗粒在宫颈癌小鼠模型中显示出预防和治疗效果。
Vaccine. 2012 Aug 3;30(36):5417-24. doi: 10.1016/j.vaccine.2012.06.010. Epub 2012 Jun 17.
10
Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.一种针对宫颈癌的免疫策略，涉及一种表达高水平人乳头瘤病毒16型E6和E7稳定融合蛋白的甲病毒载体。
Gene Ther. 2002 Jan;9(2):85-94. doi: 10.1038/sj.gt.3301627.
引用本文的文献
1
Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.重组肽生产平台与位点特异性白蛋白缀合相结合，可实现长效治疗性肽的便捷生产。
Pharmaceutics. 2020 Apr 16;12(4):364. doi: 10.3390/pharmaceutics12040364.
2
Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity against human papillomavirus 16-associated tumor.用携带重组白细胞介素 12 和 E7 的腺病毒载体免疫可增强针对人乳头瘤病毒 16 相关肿瘤的抗肿瘤免疫。
Cancer Res Treat. 2005 Feb;37(1):63-70. doi: 10.4143/crt.2005.37.1.63. Epub 2005 Feb 28.
3
Expression of a recombinant elastin-like protein in pichia pastoris.毕赤酵母中重组弹性蛋白样蛋白的表达。
Biotechnol Prog. 2009 Nov-Dec;25(6):1810-8. doi: 10.1002/btpr.208.
4
Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.用与人乳头瘤病毒16型E6和E7癌蛋白对应的合成肽进行鼻内免疫可诱导全身和黏膜细胞免疫反应以及肿瘤保护。
Vaccine. 2007 Apr 30;25(17):3302-10. doi: 10.1016/j.vaccine.2007.01.010. Epub 2007 Jan 24.
5
Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.用表达钙网蛋白-人乳头瘤病毒16 E7融合蛋白的腺病毒载体进行疫苗接种可根除小鼠体内表达E7的已建立肿瘤。
Cancer Immunol Immunother. 2007 Jul;56(7):997-1007. doi: 10.1007/s00262-006-0247-2. Epub 2006 Dec 5.
6
Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.在表达人乳头瘤病毒E7的动物肿瘤模型中，增强抗肿瘤保护性免疫需要抗原优化和溶酶体靶向。
Immunology. 2005 Oct;116(2):255-66. doi: 10.1111/j.1365-2567.2005.02219.x.
7
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.含免疫刺激复合物佐剂的重组NY-ESO-1蛋白可在人体内诱导广泛的整合抗体以及CD4(+)和CD8(+) T细胞反应。
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702. doi: 10.1073/pnas.0403572101. Epub 2004 Jul 13.
8
Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.HLA转基因小鼠在内源性加工的人乳头瘤病毒16型E7蛋白的HLA限制性细胞毒性T细胞表位呈递中的局限性
Immunology. 2002 Aug;106(4):526-36. doi: 10.1046/j.1365-2567.2002.01442.x.
9
Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.表达不同形式人乳头瘤病毒16型（HPV-16）E7的痘苗病毒可使已形成的HPV-16永生化肿瘤在体内消退，这与归巢至肿瘤部位的CD8(+) T细胞反应增强相关。
J Virol. 2001 Oct;75(20):9654-64. doi: 10.1128/JVI.75.20.9654-9664.2001.
本文引用的文献
1
Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term.疫苗诱导的Th1型反应在短期内比Th2型反应占主导，而预先存在的Th2反应在长期内占主导。
Scand J Immunol. 1998 May;47(5):459-65. doi: 10.1046/j.1365-3083.1998.00327.x.
2
Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7.与来自人乳头瘤病毒E7的肽结合的视网膜母细胞瘤肿瘤抑制口袋结构域的结构
Nature. 1998 Feb 26;391(6670):859-65. doi: 10.1038/36038.
3
A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe.一种从在粟酒裂殖酵母中表达的“高危和低危”人乳头瘤病毒类型中纯化E7蛋白的通用方案。
Protein Expr Purif. 1997 Jul;10(2):192-201. doi: 10.1006/prep.1997.0731.
4
E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.在表皮中持续表达的人乳头瘤病毒16型E7癌蛋白对E7特异性B细胞或T细胞受体库，以及对用E7蛋白免疫后诱导或维持的免疫反应均无影响。
Virology. 1997 Apr 28;231(1):155-65. doi: 10.1006/viro.1997.8491.
5
Rapid, efficient, large-scale purification of unfused, non-denatured E7 protein of cottontail rabbit papillomavirus.快速、高效、大规模纯化棉尾兔乳头瘤病毒未融合、非变性的E7蛋白。
J Virol Methods. 1996 Mar;57(1):61-70. doi: 10.1016/0166-0934(95)01965-0.
6
Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production.肽聚合有助于整合到免疫刺激复合物中，并增加抗原特异性IgG2a的产生。
Vaccine. 1995;13(15):1460-7. doi: 10.1016/0264-410x(95)00029-z.
7
8
The anomalous electrophoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of acidic amino acid residues.人乳头瘤病毒16型E7蛋白异常的电泳行为归因于酸性氨基酸残基的高含量。
Biochem Biophys Res Commun. 1993 May 14;192(3):1380-7. doi: 10.1006/bbrc.1993.1569.
9
10
Structural and functional characterization of the HPV16 E7 protein expressed in bacteria.在细菌中表达的人乳头瘤病毒16型E7蛋白的结构与功能特性
J Biol Chem. 1993 Dec 5;268(34):26018-25.
Zotero 插件